R&D Opportunity costs of gene therapies. Where do we go from her... Over 30 gene therapies have received regulatory approval.
Sales & Marketing How data is critical to commercialising drugs for rare disea... Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.
Sales & Marketing Why commercialisation is the next frontier for digital innov... In March, Cigna and its pharmacy benefit manager subsidiary Evernorth announced plans to limit spending increases on GLP-1 drugs at 15% per year.
R&D Embracing a new future-ready pharmacovigilance ecosystem Following her attendance at DIA Europe 2024, Humaira Qureshi from Qinecsa Solutions, discusses the historic challenges of pharmacovigilance and embracing a new future-ready ecosystem.
R&D How to optimise commercial-scale ATMP manufacturing through ... This is the second part of our series, "The ATMP Manufacturer's Guide to Commercialisation and cGMP Compliance".
Sales & Marketing Embracing generative AI will enhance, not replace, the human... Discussions about the impact of AI have gained prominence this year.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.